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Background: Although percutaneous renal biopsy remains an essential tool in the diagnosis and treatment of renal
diseases, in recent times the traditional procedure of nephrologists has been performed by non-nephrologists
rather than nephrologists at many institutions. The present study assessed the safety and adequacy of tissue yield
during percutaneous renal biopsy according to practitioners and techniques based on ultrasound.
Methods: This study included 658 native renal biopsies performed from 2005 to 2010 at a single centre. The
biopsies were performed by nephrologists or expert ultrasound radiologists using the ultrasound-marked blind or
real-time ultrasound-guided techniques.
Results: A total of 271 ultrasound-marked blind biopsies were performed by nephrologists, 170 real-time
ultrasound-guided biopsies were performed by nephrologists, and 217 real-time ultrasound-guided biopsies were
performed by radiologists during the study period. No differences in post-biopsy complications such as haematoma,
need for transfusion and intervention, gross haematuria, pain, or infection were observed among groups. Glomerular
numbers of renal specimens from biopsies performed by nephrologists without reference to any technique were
higher than those obtained from real-time ultrasound-guided biopsies performed by expert ultrasound radiologists.
Conclusions: Percutaneous renal biopsy performed by nephrologists was not inferior to that performed by expert
ultrasound radiologists as related to specimen yield and post-biopsy complications.
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Since the first report by Iversen and Brun in 1951, percu-
taneous renal biopsy has made many contributions to the
diagnosis and management of patients with renal diseases
[1,2]. The impact of renal biopsy has been established, and
this procedure influences the appearance of nephrology as
a specialty [3]. Indeed, Brun, a pioneer who first success-
fully performed a major series of renal biopsies, was one
of the first nephrologists [3].
In recent times percutaneous renal biopsies have been
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unless otherwise stated.at many institutions. Approximately 40% of biopsies done
in the United States in 1993 were performed by radiologists
[3]. A survey that determined who is performing kidney bi-
opsies at university hospitals in Korea showed that only
26.1% of renal biopsies are performed by nephrologists and
42.9% of renal biopsies are performed by radiologists [4].
Why has the initiative for percutaneous renal biopsy gone
to radiologists? The probable reason is that nephrologists
have lost interest in the renal biopsy procedure possibly be-
cause they became occupied elsewhere or are reluctant to
take the procedure-related risk. Many nephrologists do not
feel the need to personally perform percutaneous renal bi-
opsies as there is a need for nephrologists in the field of
renal replacement therapy such as haemodialysis, peri-
toneal dialysis and kidney transplantation [3]. Furthermore,
some nephrologists have preconceived notions that theyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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imaging devices such as ultrasound (US) [4]. Young ne-
phrologists inexperienced with the biopsy technique and
US may be reluctant to become involved with an invasive
procedure due to fear of post-biopsy complications [4].
The aim of this study was to show whether renal bi-
opsy performed by nephrologists is as safe and effective
as that performed by radiologists. We compared the
safety and adequacy of glomerular yield from percutaneous
renal biopsy between cases performed by nephrologists
and those performed by radiologists. Some renal biopsies
had been performed by nephrologists at our teaching hos-
pital, whereas others had been performed by radiologists.
In cases performed by nephrologists, percutaneous renal
biopsy was done under real-time US-guidance or blindly
according to their individual preference.Methods
Study population
This analysis included all adult patients who underwent
percutaneous native renal biopsies at The Catholic
University of Korea St. Mary’s Hospital during the 6-year
period from January 2005 to December 2010. During the
study period, renal biopsies were never performed in the
patients with polycystic kidneys, a single kidney, and those
who were pregnant. Biopsies of a transplanted kidney or
right kidney and transjugular renal biopsies were ex-
cluded. In addition, 1-day case renal biopsies without hos-
pitalisation were not included. At our institution, it was
for attending nephrologists to decide how to perform
renal biopsies of their assigned patients in the light of their
own preference for the procedure. A total of 658 native
renal biopsies were performed. Among them, 441 were
performed by nephrologists and 217 by radiologists
(Group III). The 441 cases performed by nephrologists
included 271 cases of blind biopsy (Group I) and 170
cases of a real-time US-guided procedure (Group II).
Haemoglobin, haematocrit, platelet count and inter-
national normalized ratio (INR) were measured prior to
biopsy to minimize the risk of biopsy-related bleeding.
Levels of serum creatinine, blood urea nitrogen (BUN)
and 24-hour urinary protein were also included at the
time biopsy. Kidney function was determined using an
abbreviated equation developed using data from the
Modification of Diet in Renal Disease study to estimate
glomerular filtration rate [5]. Aspirin or other anti-platelet
agents were withdrawn for at least 7 days before the
procedure. In cases of hypertension under treatment, the
biopsy was performed when blood pressure < 140/90 mmHg
was achieved. Patients lay in a bed on their back for at
least 8 hours following the biopsy. Informed consent
was mandatory and was obtained from all patients. This
retrospective study was approved by the InstitutionalReview Board of The Catholic University of Korea St.
Mary’s Hospital (No. OC11RISI0037).
Biopsy technique
All patients had prior diagnostic US or computed tom-
ography (CT) to exclude patients with a structural cause
of renal insufficiency and to avoid biopsy of single or
small kidneys. The biopsy was performed in the prone
position with patients lying with their abdomen on a
firm pillow. The lower pole of the left kidney was lo-
cated by US. After disinfecting the skin, lidocaine was
injected subcutaneously, and subsequently deeper to-
wards the kidney. A small incision was made to facilitate
introducing the biopsy needle.
In cases performed by US-marked blind renal biopsy,
a nephrologist advanced the probe needle perpendicu-
larly through the skin after marking the skin over the
lower pole of the left kidney under US guidance. The bi-
opsy needle was properly placed in the renal capsule by
feeling the resistance of solid tissue or by observing
respiratory excursion of the needle. After estimating
depth from the skin, the probe needle was withdrawn,
and the 14 G needle of the automated biopsy gun (C. R.
Bard, Inc., Murray Hill, NJ, USA) was advanced to the
previously estimated depth. When patients were asked
to hold their breath, the gun was fired, and the needle
was removed.
The procedures were similar between nephrologists
and radiologists for real-time US-guided renal biopsy.
After local anaesthesia, a practitioner advanced the auto-
mated biopsy needle to the lower pole of the left kidney
capsule under renal-time US guidance, and then the bi-
opsy gun with 14 G needle was fired. Nephrologists con-
ducted the biopsy procedure holding the US transducer
in the left hand and the biopsy gun in the right hand,
while radiologists performed the biopsy with or without
using the disinfected biopsy needle bracket that attached
to the transducer.
In all cases performed by nephrologists, a first- or
second-year fellow conducted the entire procedure. When
the renal biopsy was requested by the Department of
Radiology, all cases were performed with a real-time US-
guided procedure by attending radiologists whose major
area of expertise was abdominal radiology and US. All
practitioners, both nephrologists and radiologist, have
been requested to obtain two specimens of the kidney. In
all renal biopsies performed by radiologists, a nephrology
fellow has observed the whole process of the procedure
and checked the obtained specimens with naked eye.
When the renal specimen was deemed inadequate by
gross visual inspection, the nephrology fellow made a re-
quest to the radiologist for additional pass. Consequently,
the average of two renal specimens was obtained. After
the procedure, the specimens were hand-delivered by







Age, years 35.8 ± 14.4 38.6 ± 15.0 36.4 ± 15.9
Male 145 (53.5) 89 (52.4) 112 (51.6)
Weight, kg 62.4 ± 11.2 63.1 ± 13.2 63.9 ± 12.5
Height, cm 165.0 ± 8.8 165.0 ± 9.6 164.5 ± 10.0
BMI, kg/m2 22.9 ± 3.3 23.0 ± 3.7 23.5 ± 3.8
Blood pressure
Systolic, mmHg 118 ± 15 119 ± 14 117 ± 17
Diastolic, mmHg 74 ± 11 74 ± 12 74 ± 11
Comorbid conditions
Diabetes 5 (1.8) 14 (8.2)a 8 (3.8)
Hypertension 55 (20.3) 40 (23.5) 42 (19.8)
SLE 30 (11.1) 30 (17.6)b 11 (5.1)
Chronic liver disease 10 (3.7) 6 (3.5) 7 (3.2)
Data are presented as mean ± standard deviation or number (percentage).
aGroup II versus Group I, p < 0.005.
bGroup II versus Group III, p = 0.0005.
BMI, body mass index, SLE, systemic lupus erythematosus.
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histologic evaluation.
Biopsy safety and yield
Post-biopsy US imaging was obtained to identify imme-
diate bleeding complications. After returning to the hos-
pital ward, all patients lay in bed on their backs for a
24 hour observation time, and blood pressure and pulse
rate were monitored frequently. During this time, close
observation for gross haematuria, flank and abdominal
pain, hypotension, and fever was performed. If the pa-
tient showed unstable vital and clinical signs such as
hypotension, tachycardia or abdominal pain, an immedi-
ate CT scan or US of the abdomen was obtained. Blood
transfusions or radiological intervention including renal
artery embolization were provided when clinically indi-
cated. Blood haemoglobin and haematocrit were measured
24 hours after the biopsy. Each patient had an outpatient
follow-up visit with their nephrologist within 2 weeks of
the kidney biopsy. All patients were told to visit the out-
patient clinic during the day or emergency room at night if
they suffered any newly developed symptoms including
pain or fever after discharge from the hospital. Readmission
to the hospital was allowed when clinically indicated.
Glomerular yield was expressed as the total number of
glomeruli present in the specimen. This included the
number of all glomeruli in samples as assessed by light mi-
croscopy, immunofluorescence, and electron microscopy.
Statistical analysis
Data are presented as mean ± standard deviation or range
for continuous variables. Categorical variables are pre-
sented as frequency counts and percentages. Differences
between groups were detected by analysis of variance with
Bonferrroni’s correction. Multiple linear regression was
performed to identify the variables that made an import-
ant contribution to number of glomeruli from renal spe-
cimens and to adjust for confounding variables. We
examined the association between clinical and laboratory
factors and prodedure-related complications using mul-
tiple logistic regression analysis. The variables included in
this analysis were sex, age, body mass index (BMI),
presence of diabetes, hypertension, systemic lupus ery-
thematosus (SLE) and chronic liver disease, blood pres-
sure, pre-biopsy haemoglobin, platelet count, proteinuria
and estimated glomerular filtration rate (eGFR). A p-value
< 0.05 was considered significant.
Results
Baseline characteristics of patients
The mean age of all patients was 37 years, and 4.7% of the
patients were > 65 years. Men comprised 52.6% of all bi-
opsy patients. Hypertension, diabetes, SLE, and chronic
liver disease were found in 20.8%, 4.1%, 10.8% and 3.5% ofall patients respectively. The mean BMI of all patients was
23.1 ± 3.6 kg/m2. When patient demographics in the three
renal biopsy groups were compared, the groups were simi-
lar in age, sex, weight, height, BMI, and blood pressure
(Table 1). The prevalence of diabetes was significantly
higher in Group II when compared with that of Group I.
In addition, the prevalence of SLE was significantly higher
in Group II when compared with that of Group III.
The overall mean baseline haemoglobin and haematocrit
values were 12.7 g/dL and 37.1%, respectively, whereas the
overall mean post-biopsy haemoglobin and haematocrit
values were 12.4 g/dL and 36.4%, respectively. The baseline
mean platelet count value of all patients was 245 × 103/
mm3, and the mean INR was 0.96. Mean BUN and serum
creatinine values in all biopsy patients were 20.3 mg/dL
and 1.40 mg/dL, respectively, indicating that the mean
eGFR of the patients was 77.10 ± 33.37 mL/min/1.73 m2.
The groups were similar in baseline laboratory findings in-
cluding haemoglobin, haematocrit, and serum creatinine
(Table 2). Platelet count was higher in Group II than that
in Group III. The mean INR in Group I was significantly
lower than those in Groups II and III. Although mean base-
line BUN in Group I was slightly but significantly elevated
compared to that of Group III, levels of serum creatinine
were similar among the groups. The 24-hour urinary pro-
tein in Group I was higher than those in Groups II and III.
Glomerular yield
Overall, the mean number of glomeruli obtained from
renal specimens was 25 ± 16, and the diagnostic failure
rate was 1.22%. The adequacy of renal tissue obtained by
the three groups is compared in Table 3. The mean








Prebiopsy 12.7 ± 2.3 12.7 ± 3.2 12.7 ± 2.2
Postbiopsy 12.3 ± 2.3 12.3 ± 2.5 12.5 ± 2.4
ΔHaemoglobin 0.3 ± 1.2 0.4 ± 2.3 0.1 ± 1.4
Haematocrit, %
Prebiopsy 36.8 ± 6.8 37.3 ± 6.9 37.3 ± 6.2
Postbiopsy 35.9 ± 6.6 36.6 ± 7.3 36.8 ± 6.2
ΔHaematocrit 0.5 ± 4.3 0.7 ± 2.6 0.5 ± 2.5
Platelet count, x103/mm3 247 ± 78 234 ± 69a 252 ± 72
INR 0.94 ± 0.10b 0.97 ± 0.09 0.99 ± 0.09
BUN, mg/dL 21.9 ± 17.3c 20.5 ± 12.8 18.0 ± 11.7
Serum creatinine, mg/dL
Mean ± SD 1.46 ± 1.33 1.47 ± 1.38 1.25 ± 1.17
Range 0.56-10.64 0.58-11.21 0.36-9.60
eGFR, mL/min/1.73 m2 74.07 ± 31.86 73.67 ± 32.41 83.56 ± 35.26d
24 hr Proteinuria, g/day 1.57 (0.30-4.50)e 0.86 (0.18-2.76) 1.43 (0.26-3.46)
Data are presented as mean ± standard deviation, range or median
(interquartile interquartile, IQR).
aGroup II versus Groups III, p = 0.0425.
bGroup I versus Group II, p = 0.0028 and Group I versus Group III, p < 0.0001
cGroup I versus III, p = 0.0102.
dGroup III versus Group I, p = 0.0053 and Group III versus Group II, p = 0.0111
eGroup I versus Group II, p = 0.0079 and Group I versus Group III, p = 0.0060.
INR, international normalized ratio, BUN, blood urea nitrogen, SD, standard
deviation, eGFR, estimated glomerular filtration rate.







Haematoma 10 (3.7) 10 (5.9) 12 (5.5)
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gists regardless of the method used (Groups I and II) was
significantly higher than that obtained by radiologists
(Group III). An adjusted multiple linear regression analysis
also showed the same results (Group III versus Group I or
II, p < 0.0001). No significant difference in glomerular yield
was observed between Group I and Group II (p = 0.2181).
The proportion of failure to make a final pathologic diag-
nosis was similar among all groups.
Post-biopsy complications
The overall frequency of major bleeding complications
such as development of haematoma and requirement for
transfusion or intervention was 6.8%. No cases of death
or nephrectomy occurred. As presented in Table 2, a
significant decrease in haemoglobin or haematocrit was







Number of glomeruli 26 ± 17 29 ± 17 20 ± 12a
Failure to diagnosis 5 (1.8) 1 (0.6) 2 (0.9)
Data are presented as mean ± standard deviation or number (percentage).
aGroup III versus Group II or Group III, p < 0.001.haematoma, transfusion, and intervention was not sig-
nificant among the groups (Table 4). Gross haematuria
tended to develop less often in Group II although the
inter-group difference was not significant. Procedure-
related infection such as pyelonephritis and readmission
in relation to post-biopsy complications tended to occur
more frequently in the radiologist-performed Group III,
although the difference among groups failed to show a
statistical difference. When multiple logistic regression
analysis was performed to investigate which baseline
characteristic factors were associated with post-biopsy
complications in each group, there was no factor associ-
ated with an increased risk of any complication.
Discussion
No significant differences in overall failure rate of the
pathologic diagnosis or post-biopsy complications were
observed between radiologists and nephrologists. Des-
pite no influence on the overall diagnosis, the mean
number of glomeruli obtained from renal biopsies per-
formed by nephrologists was greater than that from the
procedures performed by expert US radiologists.
Although complications can still occur and are mainly
related to bleeding, percutaneous renal biopsy remains a
relatively safe procedure with modern medical techniques
[6]. Life threatening complications in the current practice
of percutaneous renal biopsy occur in < 0.1% [6-8]. The
needle has changed over the years as a modification that
has shaped percutaneous renal biopsy into a clinically rele-
vant, safe, and effective procedure [3,6]. With the intro-
duction of automated spring-loaded cutting-needle biopsy
guns in the 1980s, it became possible to make the proced-
ure more effective diagnostically and safer [7]. In addition,
recent advances in imaging modalities have simplified the
procedure, leading to correct needle positions [9]. It is
believed that the biopsy procedure conducted under real-
time US imaging is safer and more successful than a blind
procedure that is performed after marking the skin over
the lower pole of the kidney with US [7,10]. However, our
results demonstrate that the rate of biopsy-related compli-
cations following the blind procedure by nephrologistsTransfusion 5 (1.9) 5 (2.9) 2 (0.9)
Intervention 0 (0) 0 (0) 1 (0.5)
Gross haematuria 22 (8.1) 7 (4.1) 21 (9.8)
Pain 41 (15.1) 31 (18.2) 26 (12.1)
Infection 1 (0.4) 0 (0) 3 (1.4)
Rehospitalisation 6 (2.2) 4 (2.4) 8 (3.7)
Data are presented as number (percentage).
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renal biopsies by nephrologists or radiologists, suggesting
that knowledge of accurate placement of the needle in the
kidney may be more important than the technique itself.
Regardless of the technique used, studies have reported
adequate renal tissue sampling in 80–100% of cases [11,12].
There is a question of how many glomeruli, tubules, and
vessels are necessary for an accurate diagnosis of kidney
disease. When diffuse glomerular diseases such as amyl-
oidosis and membranous glomerulonephropathy are
suspected, one glomerulus is theoretically sufficient for
diagnosis [12,13]. Some researchers insist on a mini-
mum of two tissue cores [12,14], whereas others have
said that at least 25 glomeruli are needed for most ac-
curate diagnoses [13,15,16]. Considering the random
distribution of focal glomerular diseases, many more
glomeruli are needed. Currently, there is no agreement
among institutions and investigators on the definition
of tissue adequacy. Some physicians have suggested that
native kidney samples should have at least 20 glomeruli to
exclude focal disease processes and enable an accurate
assessment of the degree glomerular involvement [9,17].
Therefore, the big challenge would be to get more glom-
eruli for an accurate histopathologic diagnosis while pre-
serving tissue structure and minimizing complications.
Several studies have investigated sample adequacy and
the number of glomeruli according to biopsy technique or
practitioner. In some institutions, nephrologists and radi-
ologists perform the renal biopsy procedure together as a
team. In biopsies that are performed by a radiologist in
concordance with a nephrologist, the nephrologist usually
advances the needle to a depth deemed proper by the ra-
diologist while the radiologist holds the transducer for
real-time US guidance [18]. According to studies from
such institutions, 11.6–21.6 glomeruli are obtained using
real-time US guidance [18-20]. In cases that the nephrolo-
gist alone performs the whole procedure by real-time US
guidance, the mean number of glomeruli obtained from
specimens is 16–18 [10,21]. Real-time US guidance is al-
ways used at institutions in which the radiologist alone
performs the whole biopsy procedure [9,22]. The mean
number of glomeruli harvested by radiologists is 15–21
per biopsy [9,21]. In contrast, a study using the US-guided
blind procedure by nephrologists showed various results
from 11 glomeruli in uncounted specimens to 33 glom-
eruli in the average of three specimens [10,11]. In our
study, we acquired > 20 glomeruli per biopsy in most
samples harvested by both nephrologists and radiologists.
However, all nephrologists-performed renal biopsies yielded
many more glomeruli compared with those obtained by
radiologists. Interestingly, the mean number of glomeruli
from a renal specimen in the nephrologist-performed
blind biopsies was comparable to that in the nephrologist-
performed real-time US guided biopsies and was evensuperior to that in the radiologist-performed real-time US
guided biopsies. If there is no difference in terms of
procedure-related complications, it is reasonable that per-
cutaneous renal biopsies should be operated by the practi-
tioner showing better tissue adequacy. More glomeruli
might affect or even change the pathologic diagnosis.
In recent years, there has been a marked trend toward
fewer nephrologist-performed renal biopsies for reasons of
liability and economics [23], and this gap has been filled by
radiologists, urologists, and even rheumatologists [23-25].
Nephrologists can make real-time decisions about the
adequacy of sample size given the suspected diagnosis
because they have a good understanding of indications,
contraindications, modifications and complications in the
procedure as well as patient condition [7,26]. More import-
antly, losing control over renal biopsy may strike at the un-
conscious sense of identity of nephrology [3]. A previous
report demonstrated that a nephrologist with proper train-
ing can perform procedures such as renal US, renal biopsy,
placement of peritoneal dialysis catheter, catheterization
for vascular access, and angioplasty safely and effectively
[27]. In this study, we also found that US localisation of a
kidney for biopsy was rapidly acquired by our nephrology
fellows, and the outcomes of the procedure by nephrolo-
gists were at least equal to those by expert US radiologists.
According to current results, all biopsies at our institution
are now being conducted by nephrologists. All nephrology
trainees need to learn the proper kidney biopsy technique
not only because of the importance of the procedure but
also because renal biopsy is one of the triggers that enable
the development of nephrology [7].
Our study had some limitations. First, this was a retro-
spective study, which could weaken the interpretation of
the results although the sample is large compared to other
studies. Second, patients were not randomly assigned to
the group, which meant that the choice of procedure
might have been biased by the practitioner’s preference
with one of the three procedures. One could postulate that
more complicated and complex cases of patients were re-
ferred to radiologists for renal biopsy but we showed that
clinical variables were similar among groups. Third, we ex-
amined patients visiting at a single institution, so further
study is required to more fully understand the gene-
ralizability of our experiences and results to other institu-
tions and clinicians. In fact, the current study was
performed in our tertiary referral centre, whose patients
would have more comorbid conditions than other insti-
tutions. However, the indications for renal biopsy would
reflect what is actually present in the nephrology com-
munity at large. Finally, the number of needle passes
was not recorded in every case. However, previous stud-
ies have reported that number of passes dose not affect
the rate of post-biopsy complications [28,29]. Despite
no documentation on the number of needle passes, we
Chung et al. BMC Nephrology 2014, 15:96 Page 6 of 6
http://www.biomedcentral.com/1471-2369/15/96also showed that there was no significant difference in
overall complications after the biopsy between nephrol-
ogists and radiologists.
Conclusions
In summary, our analysis shows that nephrologist-
performed renal biopsies resulted in a similar complica-
tion rate but greater numbers of glomeruli compared with
radiologists regardless of whether the real-time US guid-
ance or blind procedure was conducted. Because it is a
delicate issue to compare the outcomes between practi-
tioners, only one study has been reported [21], and it will
be difficult to perform additional randomized trials. It is
essential that nephrologists cooperate with other special-
ists in a variety of ways for patient care. At least, current
evidence shows that trainees like nephrology fellows, if
they have good outstanding of kidney structure and char-
acteristic, can perform the renal biopsy safely and effect-
ively, and it would be reasonable to give preference to
nephrologists with respect to the ultrasound-guided
percutaneous procedure.
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